The EHMT2 Knockout PaTu 8988t Polyclonal Cells product offers a heterogeneous CRISPR/Cas9-edited cell population with targeted disruption of the EHMT2 (G9a) gene in the human pancreatic ductal adenocarcinoma (PDAC) cell line PaTu 8988t. As a polyclonal knockout pool, this model mirrors the genetic diversity of the edited population, enabling robust functional studies without clonal selection artifacts. The use of CRISPR/Cas9-mediated gene disruption creates a loss-of-function system ideal for investigating EHMT2-dependent epigenetic mechanisms in cancer biology. Researchers can interrogate the impact of EHMT2 ablation on chromatin modifications, gene expression, and cellular phenotypes in a disease-relevant pancreatic cancer background.
The parental PaTu 8988t cell line is a widely used model of pancreatic cancer, originally derived from a liver metastasis of a human pancreatic adenocarcinoma. These cells harbor oncogenic KRAS G12V and TP53 mutations, recapitulating key genetic drivers of aggressive PDAC. The PaTu 8988t line exhibits characteristics of epithelial-to-mesenchymal transition (EMT) and metastatic potential, making it a valuable tool for studying tumor progression, invasion, and therapeutic resistance. Its established use in pancreatic cancer research ensures compatibility with a broad range of experimental protocols and reference datasets.
EHMT2 (also known as G9a) encodes a histone lysine methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/H3K9me2), repressive marks associated with heterochromatin formation. It functions in a complex with EHMT1 (GLP), and methylated H3K9 recruits HP1 proteins (CBX1/CBX3/CBX5) to compact chromatin. EHMT2 also interacts with DNMT1 and DNMT3A, linking histone and DNA methylation. Its expression is regulated by E2F1, C-MYC, and HIF-1??, and it directly silences tumor suppressors such as CDKN1A, CDH1, and BRCA1. Additionally, EHMT2 engages in crosstalk with ??-catenin, SMAD2/3, and the PI3K/AKT/mTOR pathway, integrating growth signals with gene silencing.
In PaTu 8988t cells, EHMT2-mediated H3K9 dimethylation silences tumor suppressors, driving proliferation, EMT, and metastasis. Disruption of EHMT2 allows investigation of how loss of this methyltransferase alleviates repression of genes like CDKN1A and CDH1, potentially reversing invasive phenotypes. Given the KRAS and TP53 mutant background, the knockout enables dissection of the interplay between oncogenic drivers and epigenetic silencing. Researchers can assess whether EHMT2 ablation sensitizes cells to gemcitabine or targeted agents against PI3K/AKT/mTOR or Wnt/??-catenin pathways.
Typical applications include ChIP-seq and RNA-seq to map EHMT2 target genes and altered pathways. Proliferation, migration, invasion, and flow cytometry-based cell cycle and apoptosis assays quantify functional consequences of knockout. Co-immunoprecipitation verifies interactions with EHMT1, HP1, or DNMTs, while western blotting monitors H3K9me2 and target expression. This polyclonal knockout pool is also suitable for screening G9a inhibitors and for co-treatment studies with demethylating agents or signal transduction inhibitors. For batch-specific validation and culture details, contact Ascent Research.
